ERBB2 and breast cancer: For example, being a predictive biomarker for HER2 targeted therapy, HER2 expression was assessed in advanced breast cancer patients and the results showed that a bi-directional shift in HER2 status between the primary tumor and corresponding CTCs occurred which may help to identify additional patients who could benefit from HER2 targeted therapy [10].